Tough targets sharpen performance at Roche Diagnostics
This article was originally published in Clinica
Executive Summary
A couple of businesses are not yet meeting the threshold but they still have a chance so I will not name them." The tough but fair approach of Heino von Prondzynski, head of Roche Diagnostics, leaves the company's staff in no doubt as to what is expected of them, and this approach is vindicated by the continuing strong performance of the world's largest in vitro diagnostics organisation.
You may also be interested in...
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that of rivals Medicenna were presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.